Editas Medicine Inc (EDIT)
2.44
+0.07
(+2.95%)
USD |
NASDAQ |
Nov 22, 16:00
2.435
0.00 (0.00%)
After-Hours: 20:00
Editas Medicine Revenue (TTM): 61.76M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
September 30, 2024 | 61.76M |
June 30, 2024 | 67.03M |
March 31, 2024 | 69.41M |
December 31, 2023 | 78.12M |
September 30, 2023 | 24.61M |
June 30, 2023 | 19.32M |
March 31, 2023 | 22.79M |
December 31, 2022 | 19.71M |
September 30, 2022 | 25.64M |
June 30, 2022 | 31.80M |
March 31, 2022 | 25.82M |
December 31, 2021 | 25.54M |
September 30, 2021 | 24.49M |
June 30, 2021 | 81.14M |
March 31, 2021 | 91.51M |
December 31, 2020 | 90.73M |
September 30, 2020 | 91.60M |
June 30, 2020 | 32.60M |
Date | Value |
---|---|
March 31, 2020 | 24.18M |
December 31, 2019 | 20.53M |
September 30, 2019 | 14.37M |
June 30, 2019 | 25.04M |
March 31, 2019 | 30.08M |
December 31, 2018 | 31.94M |
September 30, 2018 | 29.48M |
June 30, 2018 | 21.25M |
March 31, 2018 | 16.97M |
December 31, 2017 | 13.73M |
September 30, 2017 | 10.96M |
June 30, 2017 | 5.639M |
March 31, 2017 | 5.93M |
December 31, 2016 | 6.053M |
September 30, 2016 | 5.947M |
June 30, 2016 | 5.655M |
March 31, 2016 | 2.434M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
19.32M
Minimum
Jun 2023
91.60M
Maximum
Sep 2020
46.42M
Average
28.81M
Median
Revenue (TTM) Benchmarks
Ionis Pharmaceuticals Inc | 803.07M |
EyePoint Pharmaceuticals Inc | 45.71M |
Cassava Sciences Inc | -- |
Adverum Biotechnologies Inc | -- |
Regenxbio Inc | 84.33M |